ライフサイエンスコーパス: allergic encephalomyelitis

1 h less severe acute early-phase experimental allergic encephalomyelitis.

2 IMP1 promotes neuropathology in experimental allergic encephalomyelitis.

3 autoimmune encephalomyelitis or experimental allergic encephalomyelitis.

4 and its principal animal model, experimental allergic encephalomyelitis.

5 protection of the mice against experimental allergic encephalomyelitis.

6 immunity and protection against experimental allergic encephalomyelitis.

7 o appropriately resolve induced experimental allergic encephalomyelitis.

8 nesis of multiple sclerosis and experimental allergic encephalomyelitis.

9 immune-mediated illness such as experimental allergic encephalomyelitis.

10 ible to the active induction of experimental allergic encephalomyelitis.

11 model of MS, chronic relapsing experimental allergic encephalomyelitis.

12 chanism for the pathogenesis of experimental allergic encephalomyelitis.

13 multiple sclerosis and the marmoset model of allergic encephalomyelitis.

14 , and amyloidosis and mice with experimental allergic encephalomyelitis.

15 uestion the Th1-Th2 paradigm in experimental allergic encephalomyelitis.

16 r cells capable of transferring experimental allergic encephalomyelitis.

17 ted autoimmune diseases such as experimental allergic encephalomyelitis.

18 ein (MOG)(35\x{2013}55)-induced experimental allergic encephalomyelitis.

19 e animals were able to overcome experimental allergic encephalomyelitis.

20 lly interconvert respond during experimental allergic encephalomyelitis.

21 specific suppression of ongoing experimental allergic encephalomyelitis.

22 evere disease manifestations in experimental allergic encephalomyelitis.

23 n-reactive T cells and modulate experimental allergic encephalomyelitis.

24 ediated protection of Tregs and experimental allergic encephalomyelitis.

25 that confers resistance against experimental allergic encephalomyelitis.

26 ing a model autoimmune disease, experimental allergic encephalomyelitis.

27 DCs sustains protection against experimental allergic encephalomyelitis, a mouse model for human mult

28 vo effects of tyrphostin B42 in experimental allergic encephalomyelitis, a Th1 cell-mediated autoimmu

29 n their Point of View entitled "Experimental Allergic Encephalomyelitis: A Misleading Model of Multip

30 specific suppression of ongoing experimental allergic encephalomyelitis (an MS animal model), and the

31 meliorated adoptive transfer of experimental allergic encephalomyelitis, an animal model of MS, via T

32 eat chronic relapsing-remitting experimental allergic encephalomyelitis, an animal model of multiple

33 were effective in treatment of experimental allergic encephalomyelitis, an animal model of multiple

34 es Tregs and protects mice from experimental allergic encephalomyelitis, an animal model of multiple

35 e for oligodendrocytes (OLG) in experimental allergic encephalomyelitis, an animal model of multiple

36 al and pathological features of experimental allergic encephalomyelitis, an animal model of multiple

37 Experimental allergic encephalomyelitis, an autoimmune disorder media

38 ation of Th1 and Th2 subsets in experimental allergic encephalomyelitis, an autoimmune disorder.

39 meliorated clinical severity of experimental allergic encephalomyelitis, an effect that partially inv

40 red autoimmune disease locus in experimental allergic encephalomyelitis and experimental allergic orc

41 ector memory T (T(EM)) cells in experimental allergic encephalomyelitis and in myelin-specific T cell

42 ffective both in suppression of experimental allergic encephalomyelitis and in the treatment of relap

43 ffective both in suppression of experimental allergic encephalomyelitis and in the treatment of relap

44 We report that MOBP causes experimental allergic encephalomyelitis and is associated with multip

45 enic mice displayed more severe experimental allergic encephalomyelitis and lupus.

46 in autoimmune processes such as experimental allergic encephalomyelitis and lupus.

47 ggest that its effectiveness in experimental allergic encephalomyelitis and multiple sclerosis may be

48 imilar results correlating with experimental allergic encephalomyelitis and orchitis susceptibility w

49 a concomitant susceptibility to experimental allergic encephalomyelitis and significant protection ag

50 This is based on studies in experimental allergic encephalomyelitis and the demonstration that PB

51 mental models of demyelination, experimental allergic encephalomyelitis and Theiler's murine encephal

52 ls are generated in vivo during experimental allergic encephalomyelitis, and adoptively transferred T

53 ies such as multiple sclerosis, experimental allergic encephalomyelitis, and Alzheimer's disease, sug

54 inally, in the in vivo model of experimental allergic encephalomyelitis, anti-B7.2 mAb treatment abro

55 n a conventional mouse model of experimental allergic encephalomyelitis are dependent upon the produc

56 TMEV)-induced demyelination and experimental allergic encephalomyelitis are the principal immunologic

57 tolerance and developed severe experimental allergic encephalomyelitis as well as spontaneous autoim

58 st disappointing aspect of EAE [experimental allergic encephalomyelitis] as a potential model for MS

59 nical and pathological signs of experimental allergic encephalomyelitis by causing the deletion of en

60 cities in the marmoset model of experimental allergic encephalomyelitis, by means of a combinatorial

61 ity in animal models, including experimental allergic encephalomyelitis, collagen and adjuvant-induce

62 es in autoimmune destruction in experimental allergic encephalomyelitis, collagen-induced arthritis a

63 Chronic relapsing experimental allergic encephalomyelitis (CREAE) is an autoimmune mode

64 utoreactive T cell response and experimental allergic encephalomyelitis development in an IL-10-depen

65 in vivo of CD4+ T-cell-mediated experimental allergic encephalomyelitis disease in the SJL mouse mode

66 hat animals with ongoing active experimental allergic encephalomyelitis dramatically reduce the sever

67 adult male SJL are resistant to experimental allergic encephalomyelitis due to an APC-dependent induc

68 ceptibility to actively induced experimental allergic encephalomyelitis (EAE) and experimental allerg

69 l models of autoimmune disease, experimental allergic encephalomyelitis (EAE) and experimental myocar

70 Experimental allergic encephalomyelitis (EAE) and its human disease c

71 Experimental allergic encephalomyelitis (EAE) and multiple sclerosis

72 Experimental allergic encephalomyelitis (EAE) and Theiler's murine en

73 two autoimmune disease models, experimental allergic encephalomyelitis (EAE) and type 1 diabetes (T1

74 igen-specific effector cells in experimental allergic encephalomyelitis (EAE) are a continuing challe

75 ment of neurological disease in experimental allergic encephalomyelitis (EAE) but not during clearanc

76 )) develop less severe clinical experimental allergic encephalomyelitis (EAE) compared to either Esr1

77 fied CTL ameliorated or blocked experimental allergic encephalomyelitis (EAE) disease mediated by MBP

78 protein (CRP) protects against experimental allergic encephalomyelitis (EAE) in C57BL/6 mice.

79 stigation of the development of experimental allergic encephalomyelitis (EAE) in CD40L-deficient mice

80 cyte glycoprotein (MOG)-induced experimental allergic encephalomyelitis (EAE) in marmosets.

81 dendrocyte glycoprotein-induced experimental allergic encephalomyelitis (EAE) in normal mice.

82 on and development of relapsing experimental allergic encephalomyelitis (EAE) in SJL mice.

83 t of fatal CD4+ T cell-mediated experimental allergic encephalomyelitis (EAE) in susceptible female L

84 sing the demyelinating model of experimental allergic encephalomyelitis (EAE) in the common marmoset.

85 udy, we used uric acid to treat experimental allergic encephalomyelitis (EAE) in the PLSJL strain of

86 5- RMTCs, prevented and treated experimental allergic encephalomyelitis (EAE) induced with MBP89-101.

87 Experimental allergic encephalomyelitis (EAE) is a CD4(+) Th1 cell-me

88 Experimental allergic encephalomyelitis (EAE) is a CNS autoimmune dis

89 MS is immune mediated and that experimental allergic encephalomyelitis (EAE) is a suitable model to

90 Experimental allergic encephalomyelitis (EAE) is a T cell-mediated au

91 Experimental allergic encephalomyelitis (EAE) is a T cell-mediated au

92 Experimental allergic encephalomyelitis (EAE) is a Th1 cell-mediated

93 Experimental allergic encephalomyelitis (EAE) is a Th1-mediated infla

94 Murine experimental allergic encephalomyelitis (EAE) is a useful model for t

95 Experimental allergic encephalomyelitis (EAE) is a widely used animal

96 Experimental allergic encephalomyelitis (EAE) is an animal model for

97 cyte glycoprotein (MOG) induced experimental allergic encephalomyelitis (EAE) is an animal model for

98 Experimental allergic encephalomyelitis (EAE) is an autoimmune diseas

99 Experimental allergic encephalomyelitis (EAE) is an autoimmune diseas

100 Experimental allergic encephalomyelitis (EAE) is an inflammatory demy

101 Experimental allergic encephalomyelitis (EAE) is an inflammatory, CD4

102 Experimental allergic encephalomyelitis (EAE) is induced by T cell-me

103 inating disease of the CNS, and experimental allergic encephalomyelitis (EAE) is its principal autoim

104 Experimental allergic encephalomyelitis (EAE) is the animal model for

105 Experimental allergic encephalomyelitis (EAE) is the principal animal

106 Experimental allergic encephalomyelitis (EAE) is the principal geneti

107 cells in multiple sclerosis and experimental allergic encephalomyelitis (EAE) lesions but their role

108 Ag-specifically treating murine experimental allergic encephalomyelitis (EAE) mediated by MBP89-101-s

109 In the C57BL/6 experimental allergic encephalomyelitis (EAE) model, cGAMP encapsulat

110 erosis and in its animal model, experimental allergic encephalomyelitis (EAE) remain equivocal.

111 ic autoimmune diseases, such as experimental allergic encephalomyelitis (EAE) the principal animal mo

112 tation and T cell activation in experimental allergic encephalomyelitis (EAE) was evaluated in wild-t

113 Monophasic experimental allergic encephalomyelitis (EAE) was induced in a cohort

114 t in a second autoimmune model, experimental allergic encephalomyelitis (EAE) was induced in B10.D1-H

115 oned Th1 cells, the severity of experimental allergic encephalomyelitis (EAE) was slightly increased.

116 Gender-related differences in experimental allergic encephalomyelitis (EAE) were examined in the SJ

117 A.SW mice develop PP or SP-experimental allergic encephalomyelitis (EAE) with large areas of dem

118 Experimental allergic encephalomyelitis (EAE), a demyelinating diseas

119 Experimental allergic encephalomyelitis (EAE), a model of central ner

120 sodium channels along axons in experimental allergic encephalomyelitis (EAE), a model of multiple sc

121 ent of Ag-specific Th1 cells in experimental allergic encephalomyelitis (EAE), a model of multiple sc

122 n C57BL/6 (B6) strain-dependent experimental allergic encephalomyelitis (EAE), a model of primary pro

123 lammatory arthritis but also in experimental allergic encephalomyelitis (EAE), a murine model of mult

124 gnificantly reduced severity of experimental allergic encephalomyelitis (EAE), a murine model of mult

125 lyn gene on the development of experimental allergic encephalomyelitis (EAE), a well-established Th1

126 ils a method to actively induce experimental allergic encephalomyelitis (EAE), a widely used animal m

127 ession in Lewis rats with acute experimental allergic encephalomyelitis (EAE), an animal model for MS

128 amined in Lewis rats with acute experimental allergic encephalomyelitis (EAE), an animal model for MS

129 ive cytokines and their role in experimental allergic encephalomyelitis (EAE), an animal model for mu

130 that Tkip protects mice against experimental allergic encephalomyelitis (EAE), an animal model for mu

131 been developed that ameliorate experimental allergic encephalomyelitis (EAE), an animal model for th

132 tration of UA is therapeutic in experimental allergic encephalomyelitis (EAE), an animal model of MS.

133 spinal cords of Lewis rats with experimental allergic encephalomyelitis (EAE), an animal model of MS.

134 sts reduce clinical severity of experimental allergic encephalomyelitis (EAE), an animal model of mul

135 ocess in adoptively transferred experimental allergic encephalomyelitis (EAE), an animal model of mul

136 We examined how experimental allergic encephalomyelitis (EAE), an animal model of mul

137 hite matter from marmosets with experimental allergic encephalomyelitis (EAE), an animal model of mul

138 ocess of adoptively transferred experimental allergic encephalomyelitis (EAE), an animal model of rel

139 would be expected to exacerbate experimental allergic encephalomyelitis (EAE), an animal model of the

140 Experimental allergic encephalomyelitis (EAE), an autoimmune model of

141 to multiple sclerosis (MS) and experimental allergic encephalomyelitis (EAE), but multiple additiona

142 covery from monophasic clinical experimental allergic encephalomyelitis (EAE), can be induced to deve

143 ted a model autoimmune disease, experimental allergic encephalomyelitis (EAE), even after epitope spr

144 ed when challenged with chronic experimental allergic encephalomyelitis (EAE), in contrast with the n

145 ) of mice with actively induced experimental allergic encephalomyelitis (EAE), that expresses OX-40L.

146 d, and Ab inhibition studies in experimental allergic encephalomyelitis (EAE), the animal model for m

147 mune disease, recent studies in experimental allergic encephalomyelitis (EAE), the animal model of mu

148 autoantigen capable of inducing experimental allergic encephalomyelitis (EAE), the animal model of mu

149 mine (HA) is a key regulator of experimental allergic encephalomyelitis (EAE), the autoimmune model o

150 s and during the development of experimental allergic encephalomyelitis (EAE), the contributions of I

151 SJL/J) F(2) intercross mice to experimental allergic encephalomyelitis (EAE), the foremost animal mo

152 Experimental allergic encephalomyelitis (EAE), the principal animal m

153 Experimental allergic encephalomyelitis (EAE), the principal animal m

154 Susceptibility to experimental allergic encephalomyelitis (EAE), the principal animal m

155 component in susceptibility to experimental allergic encephalomyelitis (EAE), the principal autoimmu

156 nd relapsing-remitting forms of experimental allergic encephalomyelitis (EAE), the principal autoimmu

157 , we used a murine model of MS, experimental allergic encephalomyelitis (EAE), to assess the potentia

158 stem was devised and applied to experimental allergic encephalomyelitis (EAE), to evaluate the contri

159 lycoprotein MOG(35-55)- induced experimental allergic encephalomyelitis (EAE), we assessed clinical s

160 stem for tolerance induction in experimental allergic encephalomyelitis (EAE), we created single-chai

161 tic nerves of mice induced with experimental allergic encephalomyelitis (EAE), with a focus on long-t

162 s and inflammatory responses in experimental allergic encephalomyelitis (EAE)-induced mice.

163 ein (MBP)-specific T cells from experimental allergic encephalomyelitis (EAE)-susceptible SJL (H-2(s)

164 els along demyelinated axons in experimental allergic encephalomyelitis (EAE).

165 nduced and spontaneous forms of experimental allergic encephalomyelitis (EAE).

166 with oral glatiramer acetate in experimental allergic encephalomyelitis (EAE).

167 peptide 35-55 in CFA to induce experimental allergic encephalomyelitis (EAE).

168 cytes into the CNS of mice with experimental allergic encephalomyelitis (EAE).

169 nesis of multiple sclerosis and experimental allergic encephalomyelitis (EAE).

170 autoimmune diseases, including experimental allergic encephalomyelitis (EAE).

171 both clinical and histological experimental allergic encephalomyelitis (EAE).

172 d (FasL) in the pathogenesis of experimental allergic encephalomyelitis (EAE).

173 autoimmune diseases, including experimental allergic encephalomyelitis (EAE).

174 he optic nerves of animals with experimental allergic encephalomyelitis (EAE).

175 ses multiple sclerosis (MS) and experimental allergic encephalomyelitis (EAE).

176 onsible for the pathogenesis of experimental allergic encephalomyelitis (EAE).

177 this T cell surface molecule in experimental allergic encephalomyelitis (EAE).

178 sensitivity (DTH) responses and experimental allergic encephalomyelitis (EAE).

179 susceptibility to induction of experimental allergic encephalomyelitis (EAE).

180 effects in an autoimmune model, experimental allergic encephalomyelitis (EAE).

181 tter of the CNS and symptoms of experimental allergic encephalomyelitis (EAE).

182 s ameliorate MS-like disease in experimental allergic encephalomyelitis (EAE).

183 ne model of multiple sclerosis, experimental allergic encephalomyelitis (EAE).

184 ns and proved effective against experimental allergic encephalomyelitis (EAE).

185 in both multiple sclerosis and experimental allergic encephalomyelitis (EAE).

186 s also not available for murine experimental allergic encephalomyelitis (EAE); the low number of T ce

187 " (healthy) and "disease-like" [experimental allergic encephalomyelitis (EAE)] animals.

188 e central nervous system during experimental allergic encephalomyelitis express the C5aR mRNA.

189 ion of myelin from animals with experimental allergic encephalomyelitis had slightly lower values of

190 y resistant to the induction of experimental allergic encephalomyelitis, implying the involvement of

191 nity, particularly diabetes and experimental allergic encephalomyelitis in animal models.

192 c T cells to induce symptoms of experimental allergic encephalomyelitis in animal models.

193 ys the onset of antigen-induced experimental allergic encephalomyelitis in myelin basic protein-T cel

194 adjuvant-induced arthritis and experimental allergic encephalomyelitis in rodents.

195 After the induction of experimental allergic encephalomyelitis in SJL mice with proteolipid

196 pe switching and attenuation of experimental allergic encephalomyelitis indicate that NTB-A is import

197 usceptible to acute early-phase experimental allergic encephalomyelitis indicating that H1R signaling

198 to the amelioration of ongoing experimental allergic encephalomyelitis induced by the transfer of pr

199 aggressive T cells and reverse experimental allergic encephalomyelitis induced with free peptides.

200 ssible autoantigens, we studied experimental allergic encephalomyelitis, induced by myelin oligodendr

201 f protective cytokines prior to experimental allergic encephalomyelitis induction and decreased effec

202 and promoted protection against experimental allergic encephalomyelitis involving diverse T cell spec

203 Experimental allergic encephalomyelitis is a prototypic autoimmune di

204 re precisely map these TMEV and experimental allergic encephalomyelitis loci relative to each other,

205 tively reduces disease in a rat experimental allergic encephalomyelitis model of multiple sclerosis.

206 oxide and peroxynitrite in the experimental allergic encephalomyelitis model.

207 se of neural inflammation in an experimental allergic encephalomyelitis model.

208 utoimmune encephalopathy in the experimental allergic encephalomyelitis model.

209 endroglial glycoprotein-induced experimental allergic encephalomyelitis (MOG-EAE).

210 uptake in a murine model of AD, experimental allergic encephalomyelitis murine model of demyelination

211 vs risk of immune deviation in experimental allergic encephalomyelitis of SJL mice induced by MP4, a

212 T cell immunity, IgG1 Abs, and experimental allergic encephalomyelitis protection, and all three wer

213 MOBP-induced experimental allergic encephalomyelitis shows a severe clinical cours

214 n an adoptive transfer model of experimental allergic encephalomyelitis, stimulation of lymph node ce

215 le in T cells fully complements experimental allergic encephalomyelitis susceptibility and the produc

216 R(-/-)) are more susceptible to experimental allergic encephalomyelitis than mice sufficient for the

217 ld mice are less susceptible to experimental allergic encephalomyelitis than their wild-type counterp

218 stration in a marmoset model of experimental allergic encephalomyelitis that closely resembles the hu

219 plays a key regulatory role in experimental allergic encephalomyelitis, the autoimmune model of mult

220 plays a key regulatory role in experimental allergic encephalomyelitis, the autoimmune model of mult

221 neutral proteinase (calpain) in experimental allergic encephalomyelitis, the corresponding animal mod

222 There are a variety of forms of experimental allergic encephalomyelitis, the most commonly studied an

223 n acute and relapsing-remitting experimental allergic encephalomyelitis, the neutrophil chemoattracta

224 to histamine, a subphenotype of experimental allergic encephalomyelitis, the principal autoimmune mod

225 ofilament on thickened axons in experimental allergic encephalomyelitis tissue.

226 s or CNS of wild-type mice with experimental allergic encephalomyelitis to determine their relatednes

227 se severity in animal models of experimental allergic encephalomyelitis, type I diabetes, and several

228 r histological manifestation of experimental allergic encephalomyelitis unless pertussis toxin is inj

229 e unable to resist or alleviate experimental allergic encephalomyelitis when treated with Ig-myelin o